DOCSLIB.ORG

Maria Khan, Matthew Epperson, Disconnetted

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Maria Khan, Matthew Epperson, Disconnetted positivelyaware.com MAY+JUNE 2012 TWo EPIDEMICS IncarceratIon and HIV How the criminal justice system can play an effective role in the treatment and prevention of HIV ThE benefiTs of opT-out tesTiNg risk fAcTors for women coNfErencE Update: croi B:16.5 in T:16 in S:15 in www.egrifta.com YOU’VE WORKED TO CONTROL YOUR HIV. NOW, TIME TO WORK ON YOUR FILE NAME 0053_EGR_AD_SPD_ HIV-RELATED EXCESS BELLY FAT. PA_May_August_ In two separate clinical trials of HIV-infected people with lipodystrophy, each lasting 6 months, EGRIFTA® (tesamorelin M3.inddDATE 03.30.12 for injection) reduced HIV-related excess belly fat by an average of 18% in the rst trial, and 14% in the second trial. CLIENT This reduction in excess belly fat resulted in an approximate 1-inch reduction in waist size. Individual results may vary. On ® Egrifta average, patients on EGRIFTA did not lose weight. PART # Like HIV, HIV-related excess belly fat is a chronic condition. In clinical studies: 120127-102148 • People who used EGRIFTA® continuously for 1 year maintained their results over this time period DESCRIPTION • People who stopped taking EGRIFTA® after 6 months had their HIV-related excess belly fat come back EGRIFTA® is believed to work with your own body to produce natural growth hormone to reduce your excess belly fat. Print Ad Positively Aware - Spread SPECS Indication: EGRIFTA® is a daily injectable prescription medicine to reduce the excess abdominal fat in HIV-infected patients with lipodystrophy. Trim: 16 x 10.5” Limitations of use: Bleed: 16.5 x 11” • The impact and safety of EGRIFTA® on cardiovascular health has not been studied Safety: 15 x 9.5” • EGRIFTA® is not indicated for weight-loss management Gutter: 1” • It’s not known whether taking EGRIFTA® helps improve compliance with antiretroviral medications Colors: 4C, CMYK • EGRIFTA® is not recommended to be used in children COLOR INFO Important Risk Information • Injection-site reactions, such as redness, itching, pain, irritation, T:10.5 in T:10.5 S:9.5 in Do not use EGRIFTA® if you: bleeding, rash, and swelling. Change (rotate) your injection site to help B:11 in • Have pituitary gland tumor, pituitary gland surgery, or other problems lower your risk for injection-site reactions related to your pituitary gland ® • Have active cancer (either newly diagnosed or recurrent) or are The most common side effects of EGRIFTA include: receiving treatment for cancer • joint pain • numbness and pricking MECH. BUILT TO • Are allergic to tesamorelin or any of the ingredients in EGRIFTA®, • pain in legs and arms • nausea • swelling in your legs • vomiting 100% including mannitol or sterile water • Are pregnant or become pregnant • muscle soreness • rash PRINTED AT • tingling • itching Before using EGRIFTA , ® tell your healthcare provider if you: 100% ® • Have or have had cancer EGRIFTA will NOT cure HIV or lower your chance of passing HIV to others. • Have diabetes You are encouraged to report negative side effects of prescription • Are breastfeeding or plan to breastfeed drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. • Have kidney or liver problems • Have any other medical condition Please see Consumer Brief Summary of EGRIFTA® on following page. • Take prescription or non-prescription medicines, vitamins, or Ask your healthcare provider if EGRIFTA®, the rst herbal supplements and only FDA-approved medicine for HIV-related EGRIFTA® may cause serious side effects, including: excess belly fat, may be right for you. For more • Serious allergic reaction. Stop using EGRIFTA® and get emergency information, visit www.egrifta.com or call the help right away if you have any of the following symptoms: rash over AXIS Center at 1-877-714-AXIS (2947). your body, hives, swelling of your face or throat, shortness of breath or trouble breathing, fast heartbeat, feeling of faintness or fainting • Swelling (fl uid retention). EGRIFTA® can cause swelling in some parts of your body. Call your healthcare provider if you have an increase in joint pain, or pain or numbness in your hands or wrist (carpal tunnel syndrome) • Increase in glucose (blood sugar) intolerance and diabetes Actual patient living with HIV since 2000 120127-102148 2/12 B:16.5 in T:16 in S:15 in www.egrifta.com YOU’VE WORKED TO CONTROL YOUR HIV. NOW, TIME TO WORK ON YOUR FILE NAME 0053_EGR_AD_SPD_ HIV-RELATED EXCESS BELLY FAT. PA_May_August_ In two separate clinical trials of HIV-infected people with lipodystrophy, each lasting 6 months, EGRIFTA® (tesamorelin M3.inddDATE 03.30.12 for injection) reduced HIV-related excess belly fat by an average of 18% in the rst trial, and 14% in the second trial. CLIENT This reduction in excess belly fat resulted in an approximate 1-inch reduction in waist size. Individual results may vary. On ® Egrifta average, patients on EGRIFTA did not lose weight. PART # Like HIV, HIV-related excess belly fat is a chronic condition. In clinical studies: 120127-102148 • People who used EGRIFTA® continuously for 1 year maintained their results over this time period DESCRIPTION • People who stopped taking EGRIFTA® after 6 months had their HIV-related excess belly fat come back EGRIFTA® is believed to work with your own body to produce natural growth hormone to reduce your excess belly fat. Print Ad Positively Aware - Spread SPECS Indication: EGRIFTA® is a daily injectable prescription medicine to reduce the excess abdominal fat in HIV-infected patients with lipodystrophy. Trim: 16 x 10.5” Limitations of use: Bleed: 16.5 x 11” • The impact and safety of EGRIFTA® on cardiovascular health has not been studied Safety: 15 x 9.5” • EGRIFTA® is not indicated for weight-loss management Gutter: 1” • It’s not known whether taking EGRIFTA® helps improve compliance with antiretroviral medications Colors: 4C, CMYK • EGRIFTA® is not recommended to be used in children COLOR INFO Important Risk Information • Injection-site reactions, such as redness, itching, pain, irritation, T:10.5 in T:10.5 S:9.5 in Do not use EGRIFTA® if you: bleeding, rash, and swelling. Change (rotate) your injection site to help B:11 in • Have pituitary gland tumor, pituitary gland surgery, or other problems lower your risk for injection-site reactions related to your pituitary gland ® • Have active cancer (either newly diagnosed or recurrent) or are The most common side effects of EGRIFTA include: receiving treatment for cancer • joint pain • numbness and pricking MECH. BUILT TO • Are allergic to tesamorelin or any of the ingredients in EGRIFTA®, • pain in legs and arms • nausea • swelling in your legs • vomiting 100% including mannitol or sterile water • Are pregnant or become pregnant • muscle soreness • rash PRINTED AT • tingling • itching Before using EGRIFTA , ® tell your healthcare provider if you: 100% ® • Have or have had cancer EGRIFTA will NOT cure HIV or lower your chance of passing HIV to others. • Have diabetes You are encouraged to report negative side effects of prescription • Are breastfeeding or plan to breastfeed drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. • Have kidney or liver problems • Have any other medical condition Please see Consumer Brief Summary of EGRIFTA® on following page. • Take prescription or non-prescription medicines, vitamins, or Ask your healthcare provider if EGRIFTA®, the rst herbal supplements and only FDA-approved medicine for HIV-related EGRIFTA® may cause serious side effects, including: excess belly fat, may be right for you. For more • Serious allergic reaction. Stop using EGRIFTA® and get emergency information, visit www.egrifta.com or call the help right away if you have any of the following symptoms: rash over AXIS Center at 1-877-714-AXIS (2947). your body, hives, swelling of your face or throat, shortness of breath or trouble breathing, fast heartbeat, feeling of faintness or fainting • Swelling (fl uid retention). EGRIFTA® can cause swelling in some parts of your body. Call your healthcare provider if you have an increase in joint pain, or pain or numbness in your hands or wrist (carpal tunnel syndrome) • Increase in glucose (blood sugar) intolerance and diabetes Actual patient living with HIV since 2000 120127-102148 2/12 T:8 in S:7 in Consumer Brief Summary for EGRIFTA® (tesamorelin for injection) EGRIFTA® (eh-GRIF-tuh) – hives (tesamorelin for injection) for subcutaneous use – swelling of your face or throat – shortness of breath or trouble breathing Read the Patient Information that comes with EGRIFTA® before you start to take it – fast heartbeat and each time you get a refill. There may be new information. This leaflet does not take – feeling of faintness or fainting FILE NAME the place of talking to your healthcare provider about your medical condition or • Swelling (fluid retention).EGRIFTA ® can cause swelling in some parts of your body. 0053_EGR_AD_PI_PA_ your treatment. Call your healthcare provider if you have an increase in joint pain, or pain or ® May_August_M1.indd What is EGRIFTA ? numbness in your hands or wrist (carpal tunnel syndrome) DATE • EGRIFTA® is an injectable prescription medicine to reduce the excess in abdominal 03.27.12 fat in HIV-infected patients with lipodystrophy. EGRIFTA® contains a growth • Increase in glucose (blood sugar) intolerance and diabetes. Your healthcare provider CLIENT hormone-releasing factor (GRF) will measure your blood sugar periodically ® EMD Serono • The impact and safety of EGRIFTA on cardiovascular health has not been studied • Injection-site reactions. Change (rotate) your injection site to help lower your risk for • EGRIFTA ® is not indicated for weight-loss management PART # injection-site reactions. Call your healthcare provider for medical advice if you have • I t is not known whether taking EGRIFTA® helps improve compliance with the following symptoms around the area of the injection site: antiretroviral medications – redness – bleeding ® ® DESCRIPTION • It is not known if EGRIFTA is safe and effective in children.
Load more

Recommended publications
  • ACT up by Geoffrey W
    ACT UP by Geoffrey W. Bateman Encyclopedia Copyright © 2015, glbtq, Inc. Entry Copyright © 2004, glbtq, inc. Reprinted from http://www.glbtq.com On March 24, 1987, the AIDS Coalition To Unleash Power, or ACT UP, staged its first action in New York City on Wall Street, protesting the Food and Drug Administration and the drug company Burroughs Wellcome. Converging on the site in the hundreds, protesters passed out flyers, disrupted traffic, and drew considerable media attention. One activist even built an effigy of the head of the FDA that he hung outside a church during the protest. Through this demonstration, ACT UP initiated its direct-action strategy in the fight against the AIDS epidemic. Using bold images and confrontational tactics, ACT UP worked to promote awareness of AIDS and challenge the complacency of politicians and government officials who had yet to respond adequately to the crisis. As its statement of purpose reads, "ACT UP is a diverse, non-partisan group united in anger and committed to direct action to end the AIDS crisis. We protest and demonstrate; we meet with government and public health officials; we research and distribute the latest medical information; we are not silent." Targeting Wall Street allowed ACT UP to highlight one of the most pressing needs of those living with AIDS in the late 1980s--effective and affordable drug treatment. Because of FDA policies, Burroughs Wellcome was the only company that made and sold AZT. The high cost of the drug--anywhere from $10,000 to $13,000 a year for one patient--and the belief that it was the only treatment option available prompted New York City activists to target this monopoly.
    [Show full text]
  • Larry Kramer Interview Number
    A PROGRAM OF MIX – THE NEW YORK LESBIAN & GAY EXPERIMENTAL FILM FESTIVAL Interviewee: Larry Kramer Interview Number: 035 Interviewer: Sarah Schulman Date of Interview: November 15, 2003 © 2004 The New York Lesbian & Gay Experimental Film Festival, Inc. ACT UP ORAL HISTORY PROJECT Interview of Larry Kramer November 15, 2003 Tape I 00:07:00 SARAH SCHULMAN: If you could say your name, how old you are, where we are and today’s date? LARRY KRAMER: My name is Larry Kramer. We are in my study, in my lover’s and my house in New Preston, Connecticut. SS: How old are you? LK: I’m 68. SS: Mazel tov. What’s today’s date? LK: That I’ve lasted this long is a major miracle. SS: And today is? LK: November 15th, 2003. SS: Well, Larry, you’ve been interviewed many times and you have a lot to say, and what we really want to do is ask you the questions that you probably have not repeated ad nauseum before and that, maybe, more of an internal conversation from people who were inside ACT UP together. So we’re not going to be asking you these generic questions or things that anybody who is interested can find other places. I just want to ask you a few background questions. When did you family come to this country? LK: My father was born in this country, and his mother was from Russia and no one knows where his father was from. And my mother came when she was four, also from Russia.
    [Show full text]
  • Download the Free QR Code Reader App
    SUMMER 2018 Trans Victories in the Trump Era Protecting everyone against discrimination at work Religious Freedom ORWELLIAN LANGUAGE IS BACK IT’S A lifesaving victory: Life After PRIDE Prison Barbershop sued after turning down SEASON client with HIV SHOP OUR BRAND-NEW MERCHANDISE SHOP.LAMBDALEGAL.ORG equality for all: priceless® Mastercard is a proud sponsor of Lambda Legal and applauds their commitment to safeguard and advance the civil rights of lesbians, gays, bisexuals, transgender people and those with HIV. Mastercard and Priceless are registered trademarks, and the circles design is a trademark of Mastercard International Incorporated. LAMBDA LEGAL IMPACT | Summer 2018 ©20128 Mastercard. All rights reserved. MCIH-17078_NYC_Pride_March_AdV1.indd 1 4/4/17 11:35 AM OVERPOWER THE BULLIES, WITH YOUR HELP generation from now, people look for opportunities to try our cases in front of juries and will ask why we didn’t do we will work with state attorneys general to protect LGBT more to fight back against people and everyone living with HIV. Trump and Pence. They are Of course, the irony is that right now we are winning Apacking the courts with judges who more cases than ever. More and more courts are holding we are distinguished primarily by their are right when we say that LGBT discrimination is a kind homophobia, transphobia and racism. of sex discrimination, and that both federal law and the Their reward is a permanent job Constitution protect us. We are winning cases for some of judging our lives. Neil Gorsuch is the most prominent, but the most vulnerable LGBTQ people in America—transgen- there are so many more.
    [Show full text]
  • The AIDS Epidemic at 20 Years: in the FIRST SIX MONTHS… SELECTED MILESTONES
    THE HENRY J. KAISER FAMILY 2001 Number of U.S. AIDS cases Number of U.S. AIDS-related Estimated number of Estimated number of people Estimated number of FOUNDATION reported since the beginning deaths reported since the Americans living with living with HIV/AIDS globally cumulative AIDS-related of the epidemic beginning of the epidemic HIV/AIDS deaths throughout the world 2001 The AIDS Epidemic At 20 Years: IN THE FIRST SIX MONTHS… SELECTED MILESTONES Major Sources Menlo Park, CA On June 5, 1981, the U.S. Centers for Disease Control and Prevention issued its 2400 Sand Hill Road African American AIDS Policy and Training Institute, The NIA first warning about a relatively rare form of pneumonia among a small group of Menlo Park, CA 94025 Plan, 1999; AIDS Memorial Quilt History, www.aidsquilt.com; young gay men in Los Angeles, which was later determined to be AIDS-related. 650 854-9400 tel AIDS Project Los Angeles, APLA History, www.apla.org; AIDS-Arts 650 854-4800 fax Timeline, www.ArtistswithAIDS.org; American Foundation for AIDS Over the past 20 years, there have been many milestones in the HIV/AIDS epidemic. Research (amfAR); Arno, P. and Frieden, K., Against the Odds: Each of us has our own history that no single set of milestones can adequately The Story of AIDS Drug Development, Politics, and Profits, Washington, DC reflect. Yet, certain events stand out. They captured public attention, causing the Harper Collins: New York, 1992; Being Alive Los Angeles; Global 1450 G Street NW Health Council; Joint United Nations Programme on HIV/AIDS Suite 250 nation – and indeed the world – to stop and take notice.
    [Show full text]
  • Innovations May 2018
    INNOVATIONS MAY 2018 The Passing of a Pioneer Remembering Dr. Mathilde Krim Also Inside: A Trove of Data on the Opioid Epidemic Bioengineering Projects Advance Why Has Asia Fallen Behind on HIV/AIDS? amfAR, The Foundation for AIDS Research amfar.org COVER STORY 10 -11 MAY 2018 Dr. Mathilde Krim, AIDS Research The biannual newsletter of amfAR, Pioneer and Human Rights Leader, 1926−2018 The Foundation for AIDS Research amfAR’s Founding Chairman, who died peacefully at 120 Wall Street, 13th Floor her home on Long Island on January 15, was New York, NY 10005-3908 “one of the real heroes in this long struggle.” T: (212) 806-1600 F: (212) 806-1601 1100 Vermont Ave. NW Suite 600 POLICY Washington, DC 20005 T: (202) 331-8600 F: (202) 331-8606 4 Huge Gaps in Access to Opioid Addiction Treatment 5 Assessing the Impact of Medicaid Expansion on the TREAT Asia Opioid Epidemic Exchange Tower 388 Sukhumvit Road 6 amfAR Lends Data Expertise to PEPFAR Planning Process Suite 2104 Klongtoey, Bangkok 10110 Thailand T: (+66) 2 663-7561 RESEARCH F: (+66) 2 663-7562 www.amfar.org 7 amfAR Renews Investment in Bioengineering Approaches to Curing HIV Innovations Staff: 8 Researchers Report Progress at Cure Summit Andrew McInnes, Editor Megan Trusdell, Senior Staff Writer 9 Can “the Berlin Patient’s” Cure Be Replicated? Claudia Kaplan, Senior Staff Writer 12 New Findings Point to Power of Antibodies Raoul Norman-Tenazas, Creative Director 12 amfAR Awards Give Boost to Promising Young Yolande Hunter-Johnson, HIV/AIDS Researchers Creative Coordinator GLOBAL 13 Study Affirms Preventive Effect of HIV Treatment 13 amfAR’s Dr.
    [Show full text]
  • AIDS Cure Research for Everyone
    . AIDS Cure Research For Everyone A Beginner’s Guide to How It’s Going And Who’s Paying for It. www.AIDSPolicyProject.org AIDS CURE RESEARCH FOR EVERYONE By Kate Krauss, Stephen LeBlanc, and John S. James, of the AIDS Policy Project Dedicated to our friend and fellow activist Edward Zold “Luck in science smiles on prepared minds.” – Louis Pasteur, via Luc Montagnier July, 2010 (v.1.03) Introduction Who knows exactly what’s going on with AIDS cure research? Not many people outside the research community. Not members of the general public, nor most health reporters. Nor the United States Congress, which decides how much to fund the National Institutes of Health. Not even most AIDS activists, who assume that the cure is decades out of reach. And most importantly, not people with AIDS themselves, millions of whose lives are at stake. Who is funding the effort to find a cure, and how much are they spending? Almost no one knows that. For these reasons, we have written this simple report to share what we have learned, so far, about the search for a cure for AIDS. This section of the report will discuss the scientific and cultural landscape that affects this research. Here, we will offer analysis and make recommendations. The second part of the report will survey the avenues of scientific research being pursued in the US. Future versions of this report will broaden its scope to include international research and funders. How Is the Research Going? The Berlin Patient and the Future The first thing to know about AIDS cure research is that the science is going well.
    [Show full text]
  • Larry Kramer's Outsider Persona
    “IF YOU HAVEN’T MADE SOMEBODY ANGRY, YOU HAVEN’T DONE SOMETHING RIGHT:” LARRY KRAMER’S OUTSIDER PERSONA Rebecca Lynn Gavrila A Thesis Submitted to the Graduate College of Bowling Green State University in partial fulfillment of The requirements for the degree of Master of Arts December 2005 Committee: Dr. Jane Barnette, Advisor Dr. Jonathan Chambers Dr. Lesa Lockford © 2005 Rebecca L. Gavrila All Rights Reserved i ABSTRACT Dr. Jane Barnette , Advisor This study offers an exploration of Larry Kramer’s outsider persona, and how that persona affected both his writings as well as public perception of the author. My argument utilizes specific texts that provide insight into various facets of Kramer’s persona, both public and private. A critical analysis of Faggots, several activist texts from the Reagan administration, and The Normal Heart provide the case studies from which I analyze Kramer’s persona(s). This thesis analyzes these works and is informed by deconstructive terms, particularly those of Paul de Man and Jacques Derrida. In addition, Philip Auslander’s notion of persona provides the definition of a term that is continually explored in each of the three chapters. The outcome of this text is not whether Kramer has an outsider persona, but how that persona developed and became a permanent feature of his writings and public appearance. Kramer’s persona changed drastically in just a few years, usually in response to cultural events affecting him directly or though his community. In the conclusion of this study, I do not merely restate my argument but show, through recent writings, how Kramer’s persona and the public’s response to his words still are relevant today.
    [Show full text]
  • In the Affirmative, Vol.6, No.7 (Mid-July/ Mid-September 1999)
    University of Southern Maine USM Digital Commons In the Affirmative Periodicals 7-15-1999 In the Affirmative, Vol.6, No.7 (Mid-July/ Mid-September 1999) Mick Martin The AIDS Project Follow this and additional works at: https://digitalcommons.usm.maine.edu/affirmative Part of the American Studies Commons, Lesbian, Gay, Bisexual, and Transgender Studies Commons, and the Public Health Commons Recommended Citation Martin, Mick and The AIDS Project, "In the Affirmative, Vol.6, No.7 (Mid-July/ Mid-September 1999)" (1999). In the Affirmative. 22. https://digitalcommons.usm.maine.edu/affirmative/22 This Book is brought to you for free and open access by the Periodicals at USM Digital Commons. It has been accepted for inclusion in In the Affirmative by an authorized administrator of USM Digital Commons. For more information, please contact [email protected]. ,,fr/ ". '" j Mid-July· to Mid-September volume VI number VII IN THE.AFFIRMATIVE a newsletter for M .aine's HIV/AIDS community PROJECT PROJECT IN THIS ISSUE PROJECT Page One PROJECT Cover Story: FTC Warning on Home HIV Test Kits. The FTC Warns PROJECT Page Two Against Son1e PROJECT By The Way, editor Mike Martin's column: "A Summer's Assumptions." Hon1e HIV Test Kits Page Three Washington Post (06/19/99) HIV Reporting in Maine. HIV Vaccine News. The U.S. Federal Trade Commission has issued a warning Page Four about some home HIV tests sold over the Internet. Maine's AIDS Hotline. In a consumer alert, the agency cautioned, "Using one of these kits could give a person who might be infected with HIV the false Page Five impression that he or she is not infected." FTC tests showed that, HIV Treatment News.
    [Show full text]
  • From AIDS to Assimilation: Representations of Male Homosexuality in Swedish Literature
    From AIDS to Assimilation: Representations of Male Homosexuality in Swedish Literature Timothy Ryan Warburton A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2014 Reading Committee: Ann-Charlotte Gavel Adams, Chair Ia Dübois Andrew Nestingen Program Authorized to Offer Degree: Scandinavian Studies ©Copyright 2014 Timothy Ryan Warburton University of Washington Abstract From AIDS to Assimilation: Representations of Male Homosexuality in Swedish Literature Timothy Ryan Warburton Chair of the Supervisory Committee: Ann-Charlotte Gavel Adams, Barbro Osher Endowed Professor of Swedish Studies Department of Scandinavian Studies This dissertation examines representations of male homosexuality in Swedish literature from 1968-2013. Since the initial visibility of homosexuality with the coming-out of Bengt Martin on Swedish television in 1968, dominant gay rights discourses in Sweden have been characterized by internal dissent over the “proper” image of male homosexuality. Rather than tracing is origins to the Stonewall Inn Riots of 1969, this dissertation focuses on the AIDS crisis as a crucial and pivotal turning point in the history of homosexuality, and as playing an integral role in the shaping of contemporary discourses on male homosexuality. The project expands the history of homosexuality in Sweden beyond legislative milestones, and analyzes key sociopolitical moments in Swedish history in order to locate the literary representations into a broader context. This study is organized into four chapters that examine the literary representations of male homosexuality. The first two chapters of this study offer analyzes of the literary history as iii well as the political and legal discourses through which ideas about homosexuality were circulated.
    [Show full text]
  • April 15, 2016 Vol
    ‘A lasting impact’ Bishop Chatard teacher Kyle Guyton remembered for his passion for theater, young people, page 7. Serving the Church in Central and Southern Indiana Since 1960 CriterionOnline.com April 15, 2016 Vol. LVI, No. 27 75¢ Share truth of family with ‘The father I always wanted’ mercy, help Youth, Terre Haute those struggling, Catholic Charities pope says employee’s bond a VATICAN CITY (CNS)—The same story of mercy, faith mercy and patience that are essential for building a strong By Natalie Hoefer family must be shown to those whose TERRE HAUTE—John Etling, director of families are in trouble Terre Haute Catholic Charities, describes the or have broken up, organization’s Ryves Youth Center this way: Pope Francis said in “The role that Ryves plays in the neighborhood his highly anticipated and the city is one of unconditional love, a postsynodal apostolic chance for children to come in and experience a exhortation. warm meal, a chance to find that there are people The document, in the community who care about them and want “ ‘Amoris Laetitia’ to see them reach their potential.” (The Joy of Love), on Former Ryves Youth Center staff member and Pope Francis Love in the Family,” now Terre Haute Catholic Charities Foodbank released on April 8, employee Dan Snider has taken that description See related story, contains no new rules and put every aspect of it into action. page 3. See related or norms. However, It all started nine years ago, says Snider, when editorial, page 4. it encourages careful “I saw this little black-haired boy dribbling down review of everything the court playing basketball.” That boy was related to family Anthony LePorte.
    [Show full text]
  • New Medications For
    HIV Medicine 2017 Stephen Raffanti, M.D., M.P.H. Medical Director, VCCC Professor of Medicine VU HIV Medicine 2017 ▪ HIV pathogenesis and why we treat HIV infection; ▪ The challenges of treating a life-long chronic infection with toxic agents; ▪ How we put all the information together to make the best choice. ▪ ART Conference Case presentations ▪ Special Programs ▪ Future Challenges AIDS: Not Just Another Disease Stonewal l Riots 1969 1981 Three Decades of Treatment Issues ▪ 1980’s: AIDS described, PCP kills 90% of pts., clinicians develop skills in diagnosing, treating and preventing complications. ▪ 1990’s: First effective treatments, patients respond, death rates drop. ▪ 2000’s: New toxicities arise, resistance is critical, adherence issues emerge, limitations of therapy become apparent. ▪ 2007: Second round of effective antiretroviral agents-integrase and CCR5 inhibitors. ▪ 2013: Serious talk of “cure”. ▪ 2015: PREP Opportunistic Infections in HIV Disease The Face Of HIV care: 1981 through 1996 ▪ Endless procession of dying young people with no hope of treatment: ▪ Minimal lab technology; ▪ AIDS defining illnesses dominated; ▪ Wasting, dementia, KS, lymphoma, CMV; ▪ Limited number of toxic inefficient medications: ▪ Antiretrovirals: AZT, ddC and ddI ▪ OI treatments: antifungals, antivirals, anti-mycobacterials ▪ Heavy imprint of stigma; ▪ Hospice expertise. The Social Political Fabric of AIDS: 1982-1987 On December 10, On July 25,1983, San Francisco General 1982, CDC reports a Hospital opens the first dedicated AIDS case of AIDS in an ward in the U.S. It is fully occupied within infant who received days Civil Rights blood transfusions. Movement Ryan WhiteAct Up, an Indiana 1954 teenagerorganizes who contracted The following week, In January 1982Stonewall , first AIDS“Occupy through the MMWR reports 22 Riots contaminatedWall blood 1969 Street” cases of unexplained American AIDS clinic is products1987 used to treat immunodeficiency and his hemophilia, is refused opportunistic established in S.F.
    [Show full text]
  • Aids, National Fear, Literary Production
    Chapter 2 aids, National Fear, Literary Production Hospitals are now so filled with aids patients that there is often a waiting period of up to a month before admission, no matter how sick you are. And, once in, patients are now more and more being treated like lepers as hospital staffs become increasingly worried that aids is infectious…. Most hospital staffs are still so badly educated about aids that they don’t know much about it … aids patients are often treated like lepers. larry kramer, “1,112 and Counting” (1983) ... Felix: Aren’t you worried about contagion? I mean, I assume I am about to become a leper. larry kramer, The Normal Heart (1985: 53) ... You know the scorn with which people treat the aids victims – as though they were suffering from leprosy…. Have you ever stopped to ask yourself how lonely these people get? Don’t we still pass for human beings deserv- ing love, attention and company … or have we degenerated so much as to drop the human status? carolyne adalla, Confessions of an aids Victim (1993: 51) ... God … Why do you dare take children and leave old wrecks like myself on this Earth? Are you the same God who with just a touch of the hand cured a man afflicted with leprosy? If so, your long record of experience should get rid of the [current aids] abomination of this world. siphiwo mahala, When a Man Cries (2007: 155) ∵ © koninklijke brill nv, leiden, ���� | doi:10.1163/97890044�018�_005 Karen Laura Thornber - 9789004420182 Downloaded from Brill.com09/28/2021 01:52:28PM via free access <UN> 96 Chapter 2 Writing
    [Show full text]